The pattern, in its most common form, started gently. A few times a year in late adolescence. Weekend use in early university. Then daily use that arrived gradually enough that no one in the social circle quite remembered when it had become daily, including the person themselves. For a long time, the use seemed to be working. It took the edge off the anxiety that had been operating since school. It made the difficult conversations easier. It produced sleep that the unmedicated version of the person had stopped producing on its own. And then, somewhere across a recent year that the person can date with surprising precision, the use stopped working in the way it once had. The anxiety did not lift between sessions; it intensified. The thinking became distorted in ways that the person had not previously experienced. The line between using to feel better and feeling worse on either side of using disappeared.

This is the territory of cannabis-induced anxiety and, in its more severe form, cannabis-induced psychosis. It is a recognised clinical category. It is increasingly common, particularly among adults who began using during the period in which the potency of available products rose substantially. And it is, in our experience, one of the more under-recognised conditions in adult behavioural health — partly because cannabis is culturally framed as relatively benign, and partly because the people most affected by it have often been minimising it for so long that they are the last to recognise the pattern.

This piece is for adults whose relationship with cannabis is no longer where they want it to be.

What Has Actually Changed in the Past Decade

The pharmacology has changed substantively. UNODC World Drug Report 2024 data and analyses by NIDA document that the average THC concentration in confiscated cannabis has risen multiple-fold over recent decades, with concentrate products routinely exceeding 60 percent THC — a clinical landscape qualitatively different from the substance studied in older epidemiological research.

The cannabis being consumed in 2026 is not the cannabis of any previous generation. The increase in average potency of widely available products, particularly the concentrates and oils that have become standard in many European and global markets, has been substantial and well-documented. THC concentrations in flower products have risen across most jurisdictions, and concentrate products routinely exceed concentrations that would have been laboratory curiosities twenty years ago.

What this means clinically is that the body of older clinical and cultural assumptions about cannabis no longer reliably applies. The pattern of effects that earlier generations associated with the substance — relaxation, mild euphoria, mild cognitive blurring, manageable next-day haze — describes a substance that is not, in most cases, what current adults are actually consuming. The product available today produces effects, in some users, that are clinically indistinguishable from psychotic disorders, including persistent anxiety states, paranoid ideation, depersonalisation and derealisation, and in some cases, full psychotic episodes requiring acute intervention.

The vulnerability is not uniform. A substantial proportion of adults can use cannabis with the surface effects only and without progressing to the more severe presentations. A meaningful minority cannot. The variables that determine which group an individual falls into include genetics, age of first use, frequency and potency of current use, co-occurring mental health conditions, and life-stage stressors that can tip an otherwise manageable use pattern into clinical territory.

The Patterns We See at Holina Village

The adults who arrive in this category typically share recognisable features. Daily or near-daily use, often for several years, of products at higher potency than they began with. A growing recognition that the use is no longer producing the effects it once did. Anxiety that is worse during periods of attempted reduction or cessation, sometimes much worse, with the person concluding that the cannabis is treating the anxiety rather than recognising that the anxiety is now substantially produced by the cannabis itself. Sleep that has become impossible without use. A felt sense, that they have not yet spoken aloud to anyone, that something more concerning than ordinary cannabis use is happening internally.

For some, the picture has escalated into clear psychotic presentations — sustained paranoid thinking, fixed false beliefs that the person can recognise as unusual but cannot dislodge, experiences of being watched or persecuted that have begun to affect daily decisions, occasionally frank perceptual disturbances. For others, the picture is less acute but is operating at a chronic level — sustained low-grade dread, depersonalisation that has not lifted in months, a relationship to one’s own thinking that has become unreliable.

Both presentations benefit from the same general clinical approach. The acute psychotic presentation requires more intensive psychiatric input, which Holina Village provides as part of the residential care where needed.

Why Outpatient Care Often Cannot Reach This

The standard outpatient pathway for cannabis-related difficulty is limited. The substance is not addressed with the seriousness that the contemporary product reality requires. Many adults in this category have, at some point, raised the use with a GP or therapist and been told that cessation should be straightforward, that the substance is not particularly addictive, or that the symptoms they are experiencing are anxiety or depression that should be treated as separate conditions.

This advice was reasonable for an older generation of cannabis. It is, in many current cases, no longer adequate. The withdrawal from sustained daily use of high-potency cannabis is not the gentle process the cultural narrative suggests. It typically includes severe insomnia, intense anxiety, irritability, anhedonia, and a particular kind of mental flatness that can persist for weeks. Without a structured setting in which to navigate this withdrawal, most adults in this category attempt cessation, encounter the withdrawal, and return to use within a few days of the attempt — often concluding, mistakenly, that the substance is not the issue because the symptoms felt worse without it.

The work that addresses this requires a setting in which the withdrawal can be navigated with appropriate clinical support, the underlying conditions that the use was self-medicating can be addressed simultaneously, and the patterns that have organised daily life around the substance can be unwound in a structured way.

What a Residential Window Provides

A residential window at Holina Village, for the cannabis presentations described in this piece, typically begins with a careful clinical assessment. Where psychotic presentations are active, psychiatric input is arranged from the outset, and antipsychotic medication may be appropriate as a stabilising measure during the early window. Where the picture is more chronic without acute psychosis, the work proceeds with non-pharmacological interventions, including sleep restoration, somatic regulation, and the structured daily routine that the campus provides.

The clinical modalities include cognitive behavioural therapy for the use patterns and the cognitive distortions, dialectical behaviour therapy for the emotional regulation, acceptance and commitment therapy for the values clarification, and motivational interviewing for the engagement with sustained cessation. Alongside these sit the experiential components — art therapy, music therapy, adventure-based work, the daily structure of life on the farm and in the orchards — that support the regulation and engagement that adults coming off heavy cannabis often respond particularly well to.

The pacing matters. A four-week stay allows for stabilisation of the acute symptoms, initial cessation, and the beginning of the underlying work. A twelve-week stay, which we more often recommend for this category, allows the longer arc of cannabis withdrawal to fully resolve and the substrate work to land before the return to the home environment.

Practical Considerations

The cost at Holina Village is €12,700 per month, with an additional €4,200 if psychiatric care is required, which for acute psychotic presentations is typically required for at least part of the stay. Residents are met at Larnaca Airport and supported through the full residential window and the structured re-entry that follows.

A Closing Note

If you have arrived at this page after the recent realisation that what was once a manageable use pattern has stopped being one, the recognition itself is information. The condition has a name, it is treatable, and the work that addresses it produces sustained results. The first conversation with our admissions team is not a commitment to anything. It is only the beginning of finding out whether what we offer is the right fit for where you actually are.